Cost-Effectiveness of Exome Sequencing versus Targeted Gene Panels for Prenatal Diagnosis of Fetal Effusions and Non-Immune Hydrops Fetalis
Although exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions, the cost-effectiveness of this approach is not known. This study aimed to evaluate the costs and outcomes of targeted gene panels vs exome se...
Saved in:
Published in | American journal of obstetrics & gynecology MFM Vol. 4; no. 6; p. 100724 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.11.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Although exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions, the cost-effectiveness of this approach is not known.
This study aimed to evaluate the costs and outcomes of targeted gene panels vs exome sequencing for prenatally diagnosed nonimmune hydrops fetalis and fetal effusions when next-generation sequencing is pursued following nondiagnostic standard nonimmune hydrops fetalis evaluations, including karyotype or chromosomal microarray.
A decision-analytical model was designed using TreeAge Pro to compare 10 genetic testing strategies, including a single test only (RASopathy, metabolic, or nonimmune hydrops fetalis–targeted gene panel or exome sequencing), sequential testing (RASopathy panel followed by nonimmune hydrops fetalis panel, metabolic panel followed by nonimmune hydrops fetalis panel, RASopathy panel followed by exome sequencing, metabolic panel followed by exome sequencing, and nonimmune hydrops fetalis panel followed by exome sequencing), and no additional genetic testing. Our theoretical cohort included cases with normal karyotype and/or microarray and excluded cases of alloimmunization and congenital viral infections. As nonimmune hydrops fetalis and fetal effusions can present throughout gestation, whereas pregnancy management options vary depending on gestational age, outcomes were calculated for 3 time intervals: 10 to 18, 18 to 22, and >22 weeks of gestation. The primary outcome was incremental cost per quality-adjusted life year. Additional outcomes included termination of pregnancy, stillbirth, neonatal death, and neonates born with mild, moderate, and severe or profound disease phenotypes. The cost-effectiveness threshold was $100,000 per quality-adjusted life year.
Among women <18 weeks of gestation, exome sequencing alone was the dominant strategy associated with the lowest costs ($221 million) and the highest quality-adjusted life years (10,288). Strategies with exome sequencing alone or as a sequential test resulted in more terminations but fewer stillbirths, neonatal deaths (NNDs), and affected infants than strategies without exome sequencing. Among women between 18 and 22 weeks of gestation, exome sequencing alone was also associated with the lowest costs ($188 million) and the highest quality-adjusted life years (8734), and similar trends were observed in pregnancy outcomes. Among patients >22 weeks of gestations, when termination was not available, exome sequencing was associated with lower costs ($300 million) and the highest quality-adjusted life years (8492). Exome sequencing was cost-effective up to a cost per test of $50,451 at <18 weeks of gestation, $50,423 at 18 to 22 weeks of gestation, and $9530 at >22 weeks of gestation. Targeted genetic panels and exome sequencing were cost-effective strategies compared with no additional genetic testing.
For cases of nonimmune hydrops fetalis and fetal effusions with nondiagnostic karyotype or microarray, next-generation sequencing was cost-effective compared with a strategy without additional genetic testing. For those that undergo next-generation sequencing, exome sequencing was the cost-effective strategy compared with all other testing strategies using targeted gene panels, leading to lower costs and fewer adverse perinatal outcomes. Exome sequencing was cost-effective in a setting without the option for pregnancy termination. These data supported the routine use of exome sequencing when next-generation sequencing is pursued for establishing a genetic diagnosis underlying otherwise unexplained nonimmune hydrops fetalis and fetal effusions. |
---|---|
AbstractList | Although exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions, the cost-effectiveness of this approach is not known.
This study aimed to evaluate the costs and outcomes of targeted gene panels vs exome sequencing for prenatally diagnosed nonimmune hydrops fetalis and fetal effusions when next-generation sequencing is pursued following nondiagnostic standard nonimmune hydrops fetalis evaluations, including karyotype or chromosomal microarray.
A decision-analytical model was designed using TreeAge Pro to compare 10 genetic testing strategies, including a single test only (RASopathy, metabolic, or nonimmune hydrops fetalis-targeted gene panel or exome sequencing), sequential testing (RASopathy panel followed by nonimmune hydrops fetalis panel, metabolic panel followed by nonimmune hydrops fetalis panel, RASopathy panel followed by exome sequencing, metabolic panel followed by exome sequencing, and nonimmune hydrops fetalis panel followed by exome sequencing), and no additional genetic testing. Our theoretical cohort included cases with normal karyotype and/or microarray and excluded cases of alloimmunization and congenital viral infections. As nonimmune hydrops fetalis and fetal effusions can present throughout gestation, whereas pregnancy management options vary depending on gestational age, outcomes were calculated for 3 time intervals: 10 to 18, 18 to 22, and >22 weeks of gestation. The primary outcome was incremental cost per quality-adjusted life year. Additional outcomes included termination of pregnancy, stillbirth, neonatal death, and neonates born with mild, moderate, and severe or profound disease phenotypes. The cost-effectiveness threshold was $100,000 per quality-adjusted life year.
Among women <18 weeks of gestation, exome sequencing alone was the dominant strategy associated with the lowest costs ($221 million) and the highest quality-adjusted life years (10,288). Strategies with exome sequencing alone or as a sequential test resulted in more terminations but fewer stillbirths, neonatal deaths (NNDs), and affected infants than strategies without exome sequencing. Among women between 18 and 22 weeks of gestation, exome sequencing alone was also associated with the lowest costs ($188 million) and the highest quality-adjusted life years (8734), and similar trends were observed in pregnancy outcomes. Among patients >22 weeks of gestations, when termination was not available, exome sequencing was associated with lower costs ($300 million) and the highest quality-adjusted life years (8492). Exome sequencing was cost-effective up to a cost per test of $50,451 at <18 weeks of gestation, $50,423 at 18 to 22 weeks of gestation, and $9530 at >22 weeks of gestation. Targeted genetic panels and exome sequencing were cost-effective strategies compared with no additional genetic testing.
For cases of nonimmune hydrops fetalis and fetal effusions with nondiagnostic karyotype or microarray, next-generation sequencing was cost-effective compared with a strategy without additional genetic testing. For those that undergo next-generation sequencing, exome sequencing was the cost-effective strategy compared with all other testing strategies using targeted gene panels, leading to lower costs and fewer adverse perinatal outcomes. Exome sequencing was cost-effective in a setting without the option for pregnancy termination. These data supported the routine use of exome sequencing when next-generation sequencing is pursued for establishing a genetic diagnosis underlying otherwise unexplained nonimmune hydrops fetalis and fetal effusions. Although exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions, the cost-effectiveness of this approach is not known.BACKGROUNDAlthough exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions, the cost-effectiveness of this approach is not known.This study aimed to evaluate the costs and outcomes of targeted gene panels vs exome sequencing for prenatally diagnosed nonimmune hydrops fetalis and fetal effusions when next-generation sequencing is pursued following nondiagnostic standard nonimmune hydrops fetalis evaluations, including karyotype or chromosomal microarray.OBJECTIVEThis study aimed to evaluate the costs and outcomes of targeted gene panels vs exome sequencing for prenatally diagnosed nonimmune hydrops fetalis and fetal effusions when next-generation sequencing is pursued following nondiagnostic standard nonimmune hydrops fetalis evaluations, including karyotype or chromosomal microarray.A decision-analytical model was designed using TreeAge Pro to compare 10 genetic testing strategies, including a single test only (RASopathy, metabolic, or nonimmune hydrops fetalis-targeted gene panel or exome sequencing), sequential testing (RASopathy panel followed by nonimmune hydrops fetalis panel, metabolic panel followed by nonimmune hydrops fetalis panel, RASopathy panel followed by exome sequencing, metabolic panel followed by exome sequencing, and nonimmune hydrops fetalis panel followed by exome sequencing), and no additional genetic testing. Our theoretical cohort included cases with normal karyotype and/or microarray and excluded cases of alloimmunization and congenital viral infections. As nonimmune hydrops fetalis and fetal effusions can present throughout gestation, whereas pregnancy management options vary depending on gestational age, outcomes were calculated for 3 time intervals: 10 to 18, 18 to 22, and >22 weeks of gestation. The primary outcome was incremental cost per quality-adjusted life year. Additional outcomes included termination of pregnancy, stillbirth, neonatal death, and neonates born with mild, moderate, and severe or profound disease phenotypes. The cost-effectiveness threshold was $100,000 per quality-adjusted life year.STUDY DESIGNA decision-analytical model was designed using TreeAge Pro to compare 10 genetic testing strategies, including a single test only (RASopathy, metabolic, or nonimmune hydrops fetalis-targeted gene panel or exome sequencing), sequential testing (RASopathy panel followed by nonimmune hydrops fetalis panel, metabolic panel followed by nonimmune hydrops fetalis panel, RASopathy panel followed by exome sequencing, metabolic panel followed by exome sequencing, and nonimmune hydrops fetalis panel followed by exome sequencing), and no additional genetic testing. Our theoretical cohort included cases with normal karyotype and/or microarray and excluded cases of alloimmunization and congenital viral infections. As nonimmune hydrops fetalis and fetal effusions can present throughout gestation, whereas pregnancy management options vary depending on gestational age, outcomes were calculated for 3 time intervals: 10 to 18, 18 to 22, and >22 weeks of gestation. The primary outcome was incremental cost per quality-adjusted life year. Additional outcomes included termination of pregnancy, stillbirth, neonatal death, and neonates born with mild, moderate, and severe or profound disease phenotypes. The cost-effectiveness threshold was $100,000 per quality-adjusted life year.Among women <18 weeks of gestation, exome sequencing alone was the dominant strategy associated with the lowest costs ($221 million) and the highest quality-adjusted life years (10,288). Strategies with exome sequencing alone or as a sequential test resulted in more terminations but fewer stillbirths, neonatal deaths (NNDs), and affected infants than strategies without exome sequencing. Among women between 18 and 22 weeks of gestation, exome sequencing alone was also associated with the lowest costs ($188 million) and the highest quality-adjusted life years (8734), and similar trends were observed in pregnancy outcomes. Among patients >22 weeks of gestations, when termination was not available, exome sequencing was associated with lower costs ($300 million) and the highest quality-adjusted life years (8492). Exome sequencing was cost-effective up to a cost per test of $50,451 at <18 weeks of gestation, $50,423 at 18 to 22 weeks of gestation, and $9530 at >22 weeks of gestation. Targeted genetic panels and exome sequencing were cost-effective strategies compared with no additional genetic testing.RESULTSAmong women <18 weeks of gestation, exome sequencing alone was the dominant strategy associated with the lowest costs ($221 million) and the highest quality-adjusted life years (10,288). Strategies with exome sequencing alone or as a sequential test resulted in more terminations but fewer stillbirths, neonatal deaths (NNDs), and affected infants than strategies without exome sequencing. Among women between 18 and 22 weeks of gestation, exome sequencing alone was also associated with the lowest costs ($188 million) and the highest quality-adjusted life years (8734), and similar trends were observed in pregnancy outcomes. Among patients >22 weeks of gestations, when termination was not available, exome sequencing was associated with lower costs ($300 million) and the highest quality-adjusted life years (8492). Exome sequencing was cost-effective up to a cost per test of $50,451 at <18 weeks of gestation, $50,423 at 18 to 22 weeks of gestation, and $9530 at >22 weeks of gestation. Targeted genetic panels and exome sequencing were cost-effective strategies compared with no additional genetic testing.For cases of nonimmune hydrops fetalis and fetal effusions with nondiagnostic karyotype or microarray, next-generation sequencing was cost-effective compared with a strategy without additional genetic testing. For those that undergo next-generation sequencing, exome sequencing was the cost-effective strategy compared with all other testing strategies using targeted gene panels, leading to lower costs and fewer adverse perinatal outcomes. Exome sequencing was cost-effective in a setting without the option for pregnancy termination. These data supported the routine use of exome sequencing when next-generation sequencing is pursued for establishing a genetic diagnosis underlying otherwise unexplained nonimmune hydrops fetalis and fetal effusions.CONCLUSIONFor cases of nonimmune hydrops fetalis and fetal effusions with nondiagnostic karyotype or microarray, next-generation sequencing was cost-effective compared with a strategy without additional genetic testing. For those that undergo next-generation sequencing, exome sequencing was the cost-effective strategy compared with all other testing strategies using targeted gene panels, leading to lower costs and fewer adverse perinatal outcomes. Exome sequencing was cost-effective in a setting without the option for pregnancy termination. These data supported the routine use of exome sequencing when next-generation sequencing is pursued for establishing a genetic diagnosis underlying otherwise unexplained nonimmune hydrops fetalis and fetal effusions. |
ArticleNumber | 100724 |
Author | Sparks, Teresa N. Norton, Mary E. Avram, Carmen M. Caughey, Aaron B. |
Author_xml | – sequence: 1 givenname: Carmen M. surname: Avram fullname: Avram, Carmen M. email: carmen.avram@duke.edu organization: Duke University Medical Center, Durham, NC (Carmen M. Avram, MD) – sequence: 2 givenname: Aaron B. surname: Caughey fullname: Caughey, Aaron B. organization: Oregon Health & Science University, Portland, OR (Aaron B. Caughey, MD, PhD) – sequence: 3 givenname: Mary E. surname: Norton fullname: Norton, Mary E. organization: University of California, San Francisco, San Francisco, CA (Mary E. Norton, MD, Teresa N. Sparks, MD, MAS) – sequence: 4 givenname: Teresa N. surname: Sparks fullname: Sparks, Teresa N. organization: University of California, San Francisco, San Francisco, CA (Mary E. Norton, MD, Teresa N. Sparks, MD, MAS) |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35995366$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kd1u1DAQhSNURH_oGyDkS26y2LGdODdIaNn-SBVUolxbXme8eJXYiydZ0WfgpfE2pZQbrmyNz5wznu-0OAoxQFG8YXTBKKvfbxdmGzeDW1S0qnKJNpV4UZxUUrVlyzk_enY_Ls4Rt5TSigkhq_pVccxl20pe1yfFr2XEsVw5B3b0ewiASKIjq59xAPIVfkwQrA8bsoeEE5I7kzYwQkcus5TcmgA9EhcTuU0QzGh68smbTYjoH2wu4FDK7hP6GJCY0JHPMZTXwzDl_qv7LsUdzjKPr4uXzvQI54_nWfHtYnW3vCpvvlxeLz_elFbUfCxlY4zoLBMtlWsunKRGtS1fS3ANV7IzleuYFAocNWvGhVJNIxUYZkxrLQN-VnyYfXfTeoDOQhiT6fUu-cGkex2N1_--BP9db-Je5xSluMoG7x4NUswbwlEPHi30fd5HnFBXDZWN5EwepGKW2hQRE7inGEb1AaXe6hmlPqDUM8rc9vb5iE9Nf8D9_UMGAHsPSaP1mRV0PmWUuov-_wm_Abyatho |
CitedBy_id | crossref_primary_10_2147_RRN_S411736 crossref_primary_10_1111_cge_14313 crossref_primary_10_1007_s40273_024_01397_5 crossref_primary_10_1080_14767058_2024_2344718 |
Cites_doi | 10.1038/ejhg.2012.285 10.1001/jama.281.21.1991 10.1002/pd.5479 10.1016/j.ajog.2014.12.018 10.1002/pd.5617 10.1016/S0140-6736(18)31940-8 10.1111/jog.12922 10.1371/journal.pone.0131402 10.1136/jmedgenet-2018-105746 10.1016/j.earlhumdev.2011.04.015 10.1002/pd.494 10.1016/j.jcv.2019.03.004 10.1002/pd.5717 10.1038/s41436-018-0352-6 10.1093/ije/dyt117 10.1016/S0140-6736(18)32042-7 10.1002/uog.23652 10.1016/j.jpeds.2018.08.041 10.1016/S0140-6736(03)15385-8 10.1002/mgg3.310 10.1111/epi.14087 10.1016/j.ajog.2014.10.1102 10.1056/NEJMoa2023643 10.1016/j.jpedsurg.2014.10.027 10.1007/s10995-012-1203-8 10.1002/pd.4675 10.1002/pd.1423 10.1016/j.whi.2014.01.003 10.1002/pd.5691 10.1002/humu.22783 10.1007/s40259-019-00344-7 10.31695/IJERAT.2020.3664 10.1034/j.1600-0412.2001.080008726.x 10.1371/journal.pone.0170843 10.1016/j.jpeds.2017.04.025 10.1002/pd.5762 10.1371/journal.pone.0114391 10.1067/mob.2002.122450 10.1016/j.ajog.2021.07.014 10.1002/ajmg.a.34438 10.1097/AOG.0000000000001029 10.1002/ajmg.a.36171 10.1016/j.pedneo.2013.07.008 10.1002/pd.2677 |
ContentType | Journal Article |
Copyright | 2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1016/j.ajogmf.2022.100724 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2589-9333 |
EndPage | 100724 |
ExternalDocumentID | 10_1016_j_ajogmf_2022_100724 35995366 S2589933322001562 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NICHD NIH HHS grantid: K12 HD001262 – fundername: NICHD NIH HHS grantid: R01 HD107190 – fundername: NHGRI NIH HHS grantid: U01 HG009599 |
GroupedDBID | 0R~ 53G AAEDW AAIAV AAKOC AALRI AAQFI AAXUO ACRLP AEBSH AFKWA AFTJW AFXIZ AIEXJ AIKHN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ AXJTR BKOJK BNPGV EBS EFJIC FDB FYGXN KOM M41 ROL SPCBC SSH SSZ T5K ~G- AFJKZ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c463t-57aa4dc14905b34f50a8993b5ef7385da2fd1548ef0ab134887758ea1aa9cc1e3 |
IEDL.DBID | AIKHN |
ISSN | 2589-9333 |
IngestDate | Tue Sep 17 21:29:28 EDT 2024 Mon Nov 04 16:45:20 EST 2024 Thu Sep 26 17:58:05 EDT 2024 Thu Nov 28 21:39:01 EST 2024 Tue Jun 18 08:51:35 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | cost-effectiveness exome sequencing prenatal diagnosis nonimmune hydrops fetalis |
Language | English |
License | Copyright © 2022 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c463t-57aa4dc14905b34f50a8993b5ef7385da2fd1548ef0ab134887758ea1aa9cc1e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938838 |
PMID | 35995366 |
PQID | 2705753158 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9938838 proquest_miscellaneous_2705753158 crossref_primary_10_1016_j_ajogmf_2022_100724 pubmed_primary_35995366 elsevier_sciencedirect_doi_10_1016_j_ajogmf_2022_100724 |
PublicationCentury | 2000 |
PublicationDate | 2022-11-01 |
PublicationDateYYYYMMDD | 2022-11-01 |
PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | American journal of obstetrics & gynecology MFM |
PublicationTitleAlternate | Am J Obstet Gynecol MFM |
PublicationYear | 2022 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Lazarin, Hawthorne, Collins, Platt, Evans, Haque (bib0038) 2014; 9 Harris, Washington, Nease, Kuppermann (bib0055) 2004; 363 McCafferty, Scott (bib0056) 2019; 33 Gold, Sen, Xu (bib0046) 2013; 17 Labcorp. 2020. Available at Roberts, Gould, Kimport, Weitz, Foster (bib0045) 2014; 24 Sparks, Thao, Lianoglou (bib0015) 2019; 21 LaDuca, Farwell, Vuong (bib0008) 2017; 12 Moreno, Kanazawa, Barini (bib0012) 2013; 161A Sohan, Carroll, De La Fuente, Soothill, Kyle (bib0031) 2001; 80 Martin, Hamilton, Osterman, Driscoll, Drake (bib0035) 2018; 67 Arjunan, Bellerose, Torres (bib0037) 2020; 40 Integrated Genetics. 2020. Available at Jelliffe-Pawlowski, Norton, Shaw (bib0033) 2015; 212 Stuurman, Joosten, van der Burgt (bib0019) 2019; 56 Fukushima, Morokuma, Fujita (bib0029) 2011; 87 Lassen, Bager, Wohlfahrt, Böttiger, Melbye (bib0043) 2013; 42 Prevention Genetics. 2020. Available at Centers for Medicare and Medicaid Services. cms.gov. 2017. Available from Mardy, Chetty, Norton, Sparks (bib0011) 2019; 39 Invitae. 2020. Available at Grobman, Dooley, Welshman, Pergament, Calhoun (bib0052) 2002; 22 Kaimal, Norton, Kuppermann (bib0053) 2015; 126 Derderian, Jeanty, Fleck (bib0028) 2015; 50 Takci, Gharibzadeh, Yurdakok (bib0017) 2014; 55 Mardy, Rangwala, Hernandez-Cruz (bib0018) 2020; 40 CGC Genetics. 2020. Available at Accessed 06/01/2020. Deden, Neveling, Zafeiropopoulou (bib0001) 2020; 40 Petrovski, Aggarwal, Giordano (bib0005) 2019; 393 ARUP Laboratories. XXX. 2020.Available at Greenwood Genetic Center. 2020. Available at Norton, Chauhan, Dashe (bib0013) 2015; 212 Deng, Fu, Yu (bib0027) 2020; 40 Michalski, Porter, Pauli (bib0041) 2002; 186 Ota, Sahara, Mabuchi, Yamamoto, Ishii, Mitsuda (bib0030) 2016; 42 Bellini, Hennekam (bib0010) 2012; 158A Phibbs, Schmitt, Cooper (bib0047) 2019; 204 Benn, Iyengar, Crowley (bib0049) 2017; 5 Sun, Ruivenkamp, Hoffer (bib0009) 2015; 36 Saigal, Stoskopf, Feeny (bib0054) 1999; 281 Kharrat, Yamamoto, Roume (bib0034) 2006; 26 Xiong, Tan, Liu (bib0042) 2019; 114 Heinonen, Ryynänen, Kirkinen (bib0032) 2000; 79 Adams, Eng (bib0007) 2019; 380 Santo, Mansour, Thilaganathan (bib0014) 2011; 31 Norton, Ziffle, Lianoglou, Hodoglugil, Devine, Sparks (bib0026) 2022; 226 Lord, McMullan, Eberhardt (bib0003) 2019; 393 Mone, Eberhardt, Hurles (bib0004) 2021; 58 The Regents of the University of California. 2020. Available at Sparks, Lianoglou, Adami (bib0006) 2020; 383 Croonen, Nillesen, Stuurman (bib0036) 2013; 21 Walker, Nelson, Jackson, Grenache, Ashwood, Schmidt (bib0048) 2015; 10 Howell, Eggers, Dalziel (bib0051) 2018; 59 GeneDx. 2020. Available at Drury, Williams, Trump (bib0002) 2015; 35 Steurer, Peyvandi, Baer (bib0016) 2017; 187 Arjunan (10.1016/j.ajogmf.2022.100724_bib0037) 2020; 40 Howell (10.1016/j.ajogmf.2022.100724_bib0051) 2018; 59 Saigal (10.1016/j.ajogmf.2022.100724_bib0054) 1999; 281 Martin (10.1016/j.ajogmf.2022.100724_bib0035) 2018; 67 Lazarin (10.1016/j.ajogmf.2022.100724_bib0038) 2014; 9 Sohan (10.1016/j.ajogmf.2022.100724_bib0031) 2001; 80 Kaimal (10.1016/j.ajogmf.2022.100724_bib0053) 2015; 126 10.1016/j.ajogmf.2022.100724_bib0021 10.1016/j.ajogmf.2022.100724_bib0020 Roberts (10.1016/j.ajogmf.2022.100724_bib0045) 2014; 24 10.1016/j.ajogmf.2022.100724_bib0025 Bellini (10.1016/j.ajogmf.2022.100724_bib0010) 2012; 158A 10.1016/j.ajogmf.2022.100724_bib0024 10.1016/j.ajogmf.2022.100724_bib0023 10.1016/j.ajogmf.2022.100724_bib0022 Sparks (10.1016/j.ajogmf.2022.100724_bib0006) 2020; 383 Michalski (10.1016/j.ajogmf.2022.100724_bib0041) 2002; 186 Walker (10.1016/j.ajogmf.2022.100724_bib0048) 2015; 10 Takci (10.1016/j.ajogmf.2022.100724_bib0017) 2014; 55 Lord (10.1016/j.ajogmf.2022.100724_bib0003) 2019; 393 Steurer (10.1016/j.ajogmf.2022.100724_bib0016) 2017; 187 Ota (10.1016/j.ajogmf.2022.100724_bib0030) 2016; 42 McCafferty (10.1016/j.ajogmf.2022.100724_bib0056) 2019; 33 Sun (10.1016/j.ajogmf.2022.100724_bib0009) 2015; 36 Stuurman (10.1016/j.ajogmf.2022.100724_bib0019) 2019; 56 Mardy (10.1016/j.ajogmf.2022.100724_bib0011) 2019; 39 10.1016/j.ajogmf.2022.100724_bib0039 Kharrat (10.1016/j.ajogmf.2022.100724_bib0034) 2006; 26 LaDuca (10.1016/j.ajogmf.2022.100724_bib0008) 2017; 12 Moreno (10.1016/j.ajogmf.2022.100724_bib0012) 2013; 161A Sparks (10.1016/j.ajogmf.2022.100724_bib0015) 2019; 21 Mone (10.1016/j.ajogmf.2022.100724_bib0004) 2021; 58 Mardy (10.1016/j.ajogmf.2022.100724_bib0018) 2020; 40 Harris (10.1016/j.ajogmf.2022.100724_bib0055) 2004; 363 Jelliffe-Pawlowski (10.1016/j.ajogmf.2022.100724_bib0033) 2015; 212 Xiong (10.1016/j.ajogmf.2022.100724_bib0042) 2019; 114 Adams (10.1016/j.ajogmf.2022.100724_bib0007) 2019; 380 10.1016/j.ajogmf.2022.100724_bib0040 Phibbs (10.1016/j.ajogmf.2022.100724_bib0047) 2019; 204 Croonen (10.1016/j.ajogmf.2022.100724_bib0036) 2013; 21 Fukushima (10.1016/j.ajogmf.2022.100724_bib0029) 2011; 87 Deng (10.1016/j.ajogmf.2022.100724_bib0027) 2020; 40 Grobman (10.1016/j.ajogmf.2022.100724_bib0052) 2002; 22 Benn (10.1016/j.ajogmf.2022.100724_bib0049) 2017; 5 10.1016/j.ajogmf.2022.100724_bib0044 Heinonen (10.1016/j.ajogmf.2022.100724_bib0032) 2000; 79 Lassen (10.1016/j.ajogmf.2022.100724_bib0043) 2013; 42 Drury (10.1016/j.ajogmf.2022.100724_bib0002) 2015; 35 Norton (10.1016/j.ajogmf.2022.100724_bib0026) 2022; 226 Santo (10.1016/j.ajogmf.2022.100724_bib0014) 2011; 31 Deden (10.1016/j.ajogmf.2022.100724_bib0001) 2020; 40 Norton (10.1016/j.ajogmf.2022.100724_bib0013) 2015; 212 Petrovski (10.1016/j.ajogmf.2022.100724_bib0005) 2019; 393 Gold (10.1016/j.ajogmf.2022.100724_bib0046) 2013; 17 Derderian (10.1016/j.ajogmf.2022.100724_bib0028) 2015; 50 10.1016/j.ajogmf.2022.100724_bib0050 |
References_xml | – volume: 58 start-page: 509 year: 2021 end-page: 518 ident: bib0004 article-title: Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis publication-title: Ultrasound Obstet Gynecol contributor: fullname: Hurles – volume: 187 start-page: 182 year: 2017 end-page: 188 ident: bib0016 article-title: Epidemiology of live born infants with nonimmune hydrops fetalis-insights from a population-based dataset publication-title: J Pediatr contributor: fullname: Baer – volume: 24 start-page: e211 year: 2014 end-page: e218 ident: bib0045 article-title: Out-of-pocket costs and insurance coverage for abortion in the United States publication-title: Womens Health Issues contributor: fullname: Foster – volume: 393 start-page: 747 year: 2019 end-page: 757 ident: bib0003 article-title: Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study publication-title: Lancet contributor: fullname: Eberhardt – volume: 226 year: 2022 ident: bib0026 article-title: Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis publication-title: Am J Obstet Gynecol contributor: fullname: Sparks – volume: 158A start-page: 597 year: 2012 end-page: 605 ident: bib0010 article-title: Non-immune hydrops fetalis: a short review of etiology and pathophysiology publication-title: Am J Med Genet A contributor: fullname: Hennekam – volume: 67 start-page: 1 year: 2018 end-page: 50 ident: bib0035 article-title: Births: final data for 2017 publication-title: Natl Vital Stat Rep contributor: fullname: Drake – volume: 79 start-page: 15 year: 2000 end-page: 18 ident: bib0032 article-title: Etiology and outcome of second trimester non-immunologic fetal hydrops publication-title: Acta Obstet Gynecol Scand contributor: fullname: Kirkinen – volume: 26 start-page: 369 year: 2006 end-page: 372 ident: bib0034 article-title: Karyotype and outcome of fetuses diagnosed with cystic hygroma in the first trimester in relation to nuchal translucency thickness publication-title: Prenat Diagn contributor: fullname: Roume – volume: 10 year: 2015 ident: bib0048 article-title: A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States publication-title: PLoS One contributor: fullname: Schmidt – volume: 31 start-page: 186 year: 2011 end-page: 195 ident: bib0014 article-title: Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents? publication-title: Prenat Diagn contributor: fullname: Thilaganathan – volume: 5 start-page: 631 year: 2017 end-page: 638 ident: bib0049 article-title: Pediatric healthcare costs for patients with 22q11.2 deletion syndrome publication-title: Mol Genet Genomic Med contributor: fullname: Crowley – volume: 380 start-page: 201 year: 2019 ident: bib0007 article-title: Next-generation sequencing to diagnose suspected genetic disorders publication-title: N Engl J Med contributor: fullname: Eng – volume: 42 start-page: 385 year: 2016 end-page: 391 ident: bib0030 article-title: Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis publication-title: J Obstet Gynaecol Res contributor: fullname: Mitsuda – volume: 40 start-page: 972 year: 2020 end-page: 983 ident: bib0001 article-title: Rapid whole exome sequencing in pregnancies to identify the underlying genetic cause in fetuses with congenital anomalies detected by ultrasound imaging publication-title: Prenat Diagn contributor: fullname: Zafeiropopoulou – volume: 21 start-page: 936 year: 2013 end-page: 942 ident: bib0036 article-title: Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings publication-title: Eur J Hum Genet contributor: fullname: Stuurman – volume: 204 start-page: 118 year: 2019 end-page: 125 ident: bib0047 article-title: Birth hospitalization costs and days of care for mothers and neonates in California, 2009-2011 publication-title: J Pediatr contributor: fullname: Cooper – volume: 383 start-page: 1746 year: 2020 end-page: 1756 ident: bib0006 article-title: Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis publication-title: N Engl J Med contributor: fullname: Adami – volume: 393 start-page: 758 year: 2019 end-page: 767 ident: bib0005 article-title: Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study publication-title: Lancet contributor: fullname: Giordano – volume: 21 start-page: 1339 year: 2019 end-page: 1344 ident: bib0015 article-title: Nonimmune hydrops fetalis: identifying the underlying genetic etiology publication-title: Genet Med contributor: fullname: Lianoglou – volume: 22 start-page: 1195 year: 2002 end-page: 1200 ident: bib0052 article-title: Preference assessment of prenatal diagnosis for Down syndrome: is 35 years a rational cutoff? publication-title: Prenat Diagn contributor: fullname: Calhoun – volume: 17 start-page: 1835 year: 2013 end-page: 1841 ident: bib0046 article-title: Hospital costs associated with stillbirth delivery publication-title: Matern Child Health J contributor: fullname: Xu – volume: 87 start-page: 571 year: 2011 end-page: 575 ident: bib0029 article-title: Short-term and long-term outcomes of 214 cases of non-immune hydrops fetalis publication-title: Early Hum Dev contributor: fullname: Fujita – volume: 42 start-page: 1070 year: 2013 end-page: 1076 ident: bib0043 article-title: Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring publication-title: Int J Epidemiol contributor: fullname: Melbye – volume: 126 start-page: 737 year: 2015 end-page: 746 ident: bib0053 article-title: Prenatal testing in the genomic age: clinical outcomes, quality of life, and costs publication-title: Obstet Gynecol contributor: fullname: Kuppermann – volume: 186 start-page: 1027 year: 2002 end-page: 1034 ident: bib0041 article-title: Costs and consequences of comprehensive stillbirth assessment publication-title: Am J Obstet Gynecol contributor: fullname: Pauli – volume: 161A start-page: 3078 year: 2013 end-page: 3086 ident: bib0012 article-title: Non-immune hydrops fetalis: a prospective study of 53 cases publication-title: Am J Med Genet A contributor: fullname: Barini – volume: 40 start-page: 803 year: 2020 end-page: 812 ident: bib0027 article-title: Nonimmune hydrops fetalis: genetic analysis and clinical outcome publication-title: Prenat Diagn contributor: fullname: Yu – volume: 114 start-page: 12 year: 2019 end-page: 20 ident: bib0042 article-title: The risk of maternal parvovirus B19 infection during pregnancy on fetal loss and fetal hydrops: a systematic review and meta-analysis publication-title: J Clin Virol contributor: fullname: Liu – volume: 56 start-page: 654 year: 2019 end-page: 661 ident: bib0019 article-title: Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update on genetic testing in the NGS era publication-title: J Med Genet contributor: fullname: van der Burgt – volume: 35 start-page: 1010 year: 2015 end-page: 1017 ident: bib0002 article-title: Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities publication-title: Prenat Diagn contributor: fullname: Trump – volume: 39 start-page: 732 year: 2019 end-page: 750 ident: bib0011 article-title: A system-based approach to the genetic etiologies of non-immune hydrops fetalis publication-title: Prenat Diagn contributor: fullname: Sparks – volume: 59 start-page: 1177 year: 2018 end-page: 1187 ident: bib0051 article-title: A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy publication-title: Epilepsia contributor: fullname: Dalziel – volume: 40 start-page: 1246 year: 2020 end-page: 1257 ident: bib0037 article-title: Evaluation and classification of severity for 176 genes on an expanded carrier screening panel publication-title: Prenat Diagn contributor: fullname: Torres – volume: 50 start-page: 50 year: 2015 end-page: 54 ident: bib0028 article-title: The many faces of hydrops publication-title: J Pediatr Surg contributor: fullname: Fleck – volume: 36 start-page: 648 year: 2015 end-page: 655 ident: bib0009 article-title: Next-generation diagnostics: gene panel, exome, or whole genome? publication-title: Hum Mutat contributor: fullname: Hoffer – volume: 40 start-page: 492 year: 2020 end-page: 496 ident: bib0018 article-title: Utility of chromosomal microarray for diagnosis in cases of nonimmune hydrops fetalis publication-title: Prenat Diagn contributor: fullname: Hernandez-Cruz – volume: 12 year: 2017 ident: bib0008 article-title: Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels publication-title: PLoS One contributor: fullname: Vuong – volume: 33 start-page: 233 year: 2019 end-page: 240 ident: bib0056 article-title: Vestronidase Alfa: a review in mucopolysaccharidosis VII publication-title: BioDrugs contributor: fullname: Scott – volume: 212 start-page: 127 year: 2015 end-page: 139 ident: bib0013 article-title: Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #7: nonimmune hydrops fetalis publication-title: Am J Obstet Gynecol contributor: fullname: Dashe – volume: 55 start-page: 108 year: 2014 end-page: 113 ident: bib0017 article-title: Etiology and outcome of hydrops fetalis: report of 62 cases publication-title: Pediatr Neonatol contributor: fullname: Yurdakok – volume: 281 start-page: 1991 year: 1999 end-page: 1997 ident: bib0054 article-title: Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents publication-title: JAMA contributor: fullname: Feeny – volume: 9 year: 2014 ident: bib0038 article-title: Systematic classification of disease severity for evaluation of expanded carrier screening panels publication-title: PLoS One contributor: fullname: Haque – volume: 363 start-page: 276 year: 2004 end-page: 282 ident: bib0055 article-title: Cost utility of prenatal diagnosis and the risk-based threshold publication-title: Lancet contributor: fullname: Kuppermann – volume: 212 year: 2015 ident: bib0033 article-title: Risk of critical congenital heart defects by nuchal translucency norms publication-title: Am J Obstet Gynecol contributor: fullname: Shaw – volume: 80 start-page: 726 year: 2001 end-page: 730 ident: bib0031 article-title: Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment publication-title: Acta Obstet Gynecol Scand contributor: fullname: Kyle – volume: 21 start-page: 936 year: 2013 ident: 10.1016/j.ajogmf.2022.100724_bib0036 article-title: Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings publication-title: Eur J Hum Genet doi: 10.1038/ejhg.2012.285 contributor: fullname: Croonen – volume: 281 start-page: 1991 year: 1999 ident: 10.1016/j.ajogmf.2022.100724_bib0054 article-title: Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents publication-title: JAMA doi: 10.1001/jama.281.21.1991 contributor: fullname: Saigal – ident: 10.1016/j.ajogmf.2022.100724_bib0021 – ident: 10.1016/j.ajogmf.2022.100724_bib0025 – ident: 10.1016/j.ajogmf.2022.100724_bib0044 – volume: 39 start-page: 732 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0011 article-title: A system-based approach to the genetic etiologies of non-immune hydrops fetalis publication-title: Prenat Diagn doi: 10.1002/pd.5479 contributor: fullname: Mardy – volume: 212 start-page: 127 year: 2015 ident: 10.1016/j.ajogmf.2022.100724_bib0013 article-title: Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #7: nonimmune hydrops fetalis publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2014.12.018 contributor: fullname: Norton – volume: 40 start-page: 492 year: 2020 ident: 10.1016/j.ajogmf.2022.100724_bib0018 article-title: Utility of chromosomal microarray for diagnosis in cases of nonimmune hydrops fetalis publication-title: Prenat Diagn doi: 10.1002/pd.5617 contributor: fullname: Mardy – volume: 393 start-page: 747 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0003 article-title: Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study publication-title: Lancet doi: 10.1016/S0140-6736(18)31940-8 contributor: fullname: Lord – volume: 42 start-page: 385 year: 2016 ident: 10.1016/j.ajogmf.2022.100724_bib0030 article-title: Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis publication-title: J Obstet Gynaecol Res doi: 10.1111/jog.12922 contributor: fullname: Ota – volume: 10 year: 2015 ident: 10.1016/j.ajogmf.2022.100724_bib0048 article-title: A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States publication-title: PLoS One doi: 10.1371/journal.pone.0131402 contributor: fullname: Walker – volume: 56 start-page: 654 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0019 article-title: Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update on genetic testing in the NGS era publication-title: J Med Genet doi: 10.1136/jmedgenet-2018-105746 contributor: fullname: Stuurman – volume: 87 start-page: 571 year: 2011 ident: 10.1016/j.ajogmf.2022.100724_bib0029 article-title: Short-term and long-term outcomes of 214 cases of non-immune hydrops fetalis publication-title: Early Hum Dev doi: 10.1016/j.earlhumdev.2011.04.015 contributor: fullname: Fukushima – volume: 79 start-page: 15 year: 2000 ident: 10.1016/j.ajogmf.2022.100724_bib0032 article-title: Etiology and outcome of second trimester non-immunologic fetal hydrops publication-title: Acta Obstet Gynecol Scand contributor: fullname: Heinonen – volume: 22 start-page: 1195 year: 2002 ident: 10.1016/j.ajogmf.2022.100724_bib0052 article-title: Preference assessment of prenatal diagnosis for Down syndrome: is 35 years a rational cutoff? publication-title: Prenat Diagn doi: 10.1002/pd.494 contributor: fullname: Grobman – volume: 114 start-page: 12 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0042 article-title: The risk of maternal parvovirus B19 infection during pregnancy on fetal loss and fetal hydrops: a systematic review and meta-analysis publication-title: J Clin Virol doi: 10.1016/j.jcv.2019.03.004 contributor: fullname: Xiong – volume: 40 start-page: 972 year: 2020 ident: 10.1016/j.ajogmf.2022.100724_bib0001 article-title: Rapid whole exome sequencing in pregnancies to identify the underlying genetic cause in fetuses with congenital anomalies detected by ultrasound imaging publication-title: Prenat Diagn doi: 10.1002/pd.5717 contributor: fullname: Deden – volume: 21 start-page: 1339 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0015 article-title: Nonimmune hydrops fetalis: identifying the underlying genetic etiology publication-title: Genet Med doi: 10.1038/s41436-018-0352-6 contributor: fullname: Sparks – volume: 42 start-page: 1070 year: 2013 ident: 10.1016/j.ajogmf.2022.100724_bib0043 article-title: Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring publication-title: Int J Epidemiol doi: 10.1093/ije/dyt117 contributor: fullname: Lassen – volume: 393 start-page: 758 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0005 article-title: Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(18)32042-7 contributor: fullname: Petrovski – volume: 58 start-page: 509 year: 2021 ident: 10.1016/j.ajogmf.2022.100724_bib0004 article-title: Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis publication-title: Ultrasound Obstet Gynecol doi: 10.1002/uog.23652 contributor: fullname: Mone – volume: 204 start-page: 118 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0047 article-title: Birth hospitalization costs and days of care for mothers and neonates in California, 2009-2011 publication-title: J Pediatr doi: 10.1016/j.jpeds.2018.08.041 contributor: fullname: Phibbs – volume: 363 start-page: 276 year: 2004 ident: 10.1016/j.ajogmf.2022.100724_bib0055 article-title: Cost utility of prenatal diagnosis and the risk-based threshold publication-title: Lancet doi: 10.1016/S0140-6736(03)15385-8 contributor: fullname: Harris – volume: 5 start-page: 631 year: 2017 ident: 10.1016/j.ajogmf.2022.100724_bib0049 article-title: Pediatric healthcare costs for patients with 22q11.2 deletion syndrome publication-title: Mol Genet Genomic Med doi: 10.1002/mgg3.310 contributor: fullname: Benn – volume: 59 start-page: 1177 year: 2018 ident: 10.1016/j.ajogmf.2022.100724_bib0051 article-title: A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy publication-title: Epilepsia doi: 10.1111/epi.14087 contributor: fullname: Howell – volume: 212 year: 2015 ident: 10.1016/j.ajogmf.2022.100724_bib0033 article-title: Risk of critical congenital heart defects by nuchal translucency norms publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2014.10.1102 contributor: fullname: Jelliffe-Pawlowski – volume: 383 start-page: 1746 year: 2020 ident: 10.1016/j.ajogmf.2022.100724_bib0006 article-title: Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis publication-title: N Engl J Med doi: 10.1056/NEJMoa2023643 contributor: fullname: Sparks – volume: 50 start-page: 50 year: 2015 ident: 10.1016/j.ajogmf.2022.100724_bib0028 article-title: The many faces of hydrops publication-title: J Pediatr Surg doi: 10.1016/j.jpedsurg.2014.10.027 contributor: fullname: Derderian – ident: 10.1016/j.ajogmf.2022.100724_bib0022 – volume: 17 start-page: 1835 year: 2013 ident: 10.1016/j.ajogmf.2022.100724_bib0046 article-title: Hospital costs associated with stillbirth delivery publication-title: Matern Child Health J doi: 10.1007/s10995-012-1203-8 contributor: fullname: Gold – ident: 10.1016/j.ajogmf.2022.100724_bib0050 – volume: 35 start-page: 1010 year: 2015 ident: 10.1016/j.ajogmf.2022.100724_bib0002 article-title: Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities publication-title: Prenat Diagn doi: 10.1002/pd.4675 contributor: fullname: Drury – volume: 26 start-page: 369 year: 2006 ident: 10.1016/j.ajogmf.2022.100724_bib0034 article-title: Karyotype and outcome of fetuses diagnosed with cystic hygroma in the first trimester in relation to nuchal translucency thickness publication-title: Prenat Diagn doi: 10.1002/pd.1423 contributor: fullname: Kharrat – volume: 24 start-page: e211 year: 2014 ident: 10.1016/j.ajogmf.2022.100724_bib0045 article-title: Out-of-pocket costs and insurance coverage for abortion in the United States publication-title: Womens Health Issues doi: 10.1016/j.whi.2014.01.003 contributor: fullname: Roberts – volume: 40 start-page: 803 year: 2020 ident: 10.1016/j.ajogmf.2022.100724_bib0027 article-title: Nonimmune hydrops fetalis: genetic analysis and clinical outcome publication-title: Prenat Diagn doi: 10.1002/pd.5691 contributor: fullname: Deng – volume: 36 start-page: 648 year: 2015 ident: 10.1016/j.ajogmf.2022.100724_bib0009 article-title: Next-generation diagnostics: gene panel, exome, or whole genome? publication-title: Hum Mutat doi: 10.1002/humu.22783 contributor: fullname: Sun – volume: 33 start-page: 233 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0056 article-title: Vestronidase Alfa: a review in mucopolysaccharidosis VII publication-title: BioDrugs doi: 10.1007/s40259-019-00344-7 contributor: fullname: McCafferty – ident: 10.1016/j.ajogmf.2022.100724_bib0040 doi: 10.31695/IJERAT.2020.3664 – volume: 67 start-page: 1 year: 2018 ident: 10.1016/j.ajogmf.2022.100724_bib0035 article-title: Births: final data for 2017 publication-title: Natl Vital Stat Rep contributor: fullname: Martin – volume: 80 start-page: 726 year: 2001 ident: 10.1016/j.ajogmf.2022.100724_bib0031 article-title: Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment publication-title: Acta Obstet Gynecol Scand doi: 10.1034/j.1600-0412.2001.080008726.x contributor: fullname: Sohan – ident: 10.1016/j.ajogmf.2022.100724_bib0023 – volume: 12 year: 2017 ident: 10.1016/j.ajogmf.2022.100724_bib0008 article-title: Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels publication-title: PLoS One doi: 10.1371/journal.pone.0170843 contributor: fullname: LaDuca – volume: 187 start-page: 182 year: 2017 ident: 10.1016/j.ajogmf.2022.100724_bib0016 article-title: Epidemiology of live born infants with nonimmune hydrops fetalis-insights from a population-based dataset publication-title: J Pediatr doi: 10.1016/j.jpeds.2017.04.025 contributor: fullname: Steurer – volume: 40 start-page: 1246 year: 2020 ident: 10.1016/j.ajogmf.2022.100724_bib0037 article-title: Evaluation and classification of severity for 176 genes on an expanded carrier screening panel publication-title: Prenat Diagn doi: 10.1002/pd.5762 contributor: fullname: Arjunan – volume: 9 year: 2014 ident: 10.1016/j.ajogmf.2022.100724_bib0038 article-title: Systematic classification of disease severity for evaluation of expanded carrier screening panels publication-title: PLoS One doi: 10.1371/journal.pone.0114391 contributor: fullname: Lazarin – volume: 186 start-page: 1027 year: 2002 ident: 10.1016/j.ajogmf.2022.100724_bib0041 article-title: Costs and consequences of comprehensive stillbirth assessment publication-title: Am J Obstet Gynecol doi: 10.1067/mob.2002.122450 contributor: fullname: Michalski – volume: 380 start-page: 201 year: 2019 ident: 10.1016/j.ajogmf.2022.100724_bib0007 article-title: Next-generation sequencing to diagnose suspected genetic disorders publication-title: N Engl J Med contributor: fullname: Adams – ident: 10.1016/j.ajogmf.2022.100724_bib0039 – volume: 226 year: 2022 ident: 10.1016/j.ajogmf.2022.100724_bib0026 article-title: Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2021.07.014 contributor: fullname: Norton – volume: 158A start-page: 597 year: 2012 ident: 10.1016/j.ajogmf.2022.100724_bib0010 article-title: Non-immune hydrops fetalis: a short review of etiology and pathophysiology publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.34438 contributor: fullname: Bellini – volume: 126 start-page: 737 year: 2015 ident: 10.1016/j.ajogmf.2022.100724_bib0053 article-title: Prenatal testing in the genomic age: clinical outcomes, quality of life, and costs publication-title: Obstet Gynecol doi: 10.1097/AOG.0000000000001029 contributor: fullname: Kaimal – volume: 161A start-page: 3078 year: 2013 ident: 10.1016/j.ajogmf.2022.100724_bib0012 article-title: Non-immune hydrops fetalis: a prospective study of 53 cases publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.36171 contributor: fullname: Moreno – volume: 55 start-page: 108 year: 2014 ident: 10.1016/j.ajogmf.2022.100724_bib0017 article-title: Etiology and outcome of hydrops fetalis: report of 62 cases publication-title: Pediatr Neonatol doi: 10.1016/j.pedneo.2013.07.008 contributor: fullname: Takci – volume: 31 start-page: 186 year: 2011 ident: 10.1016/j.ajogmf.2022.100724_bib0014 article-title: Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents? publication-title: Prenat Diagn doi: 10.1002/pd.2677 contributor: fullname: Santo – ident: 10.1016/j.ajogmf.2022.100724_bib0020 – ident: 10.1016/j.ajogmf.2022.100724_bib0024 |
SSID | ssj0002144526 |
Score | 2.2868059 |
Snippet | Although exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions,... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 100724 |
SubjectTerms | Cost-Benefit Analysis cost-effectiveness Exome Sequencing Female Fetal Diseases - diagnosis Fetal Diseases - genetics Humans Hydrops Fetalis - diagnosis Hydrops Fetalis - genetics Infant Infant, Newborn nonimmune hydrops fetalis Perinatal Death Pregnancy prenatal diagnosis Prenatal Diagnosis - methods Stillbirth |
Title | Cost-Effectiveness of Exome Sequencing versus Targeted Gene Panels for Prenatal Diagnosis of Fetal Effusions and Non-Immune Hydrops Fetalis |
URI | https://dx.doi.org/10.1016/j.ajogmf.2022.100724 https://www.ncbi.nlm.nih.gov/pubmed/35995366 https://www.proquest.com/docview/2705753158 https://pubmed.ncbi.nlm.nih.gov/PMC9938838 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBalhbGXsbX7kXUrKuxVxJYs23ksaUO6rSGsLfRNSPZ5c6F2iBNo_4b-072z7LB0jMEeLUu2fCffnaTvPjH2xQGG8RLwR1KxFZFLQdjAgkjj2OoRBhxuRLnDF7N4eh19vdE3O2zc58IQrLKz_d6mt9a6Kxl20hwuynJ4KTXOFZTCEdnmA6Md3kN3RHu1eyfn36azzVILsYLp9uA1aiKoTZ9E1yK97G39847oPKVsQQMy-puT-jMIfY6l_M05TV6zV11UyU98x9-wHaj22YuLbt_8gD2O62YlPFNxZ954XfCz-_oO-KVHU6MP44TRWDf8qoWHQ86JlJrPbYV94xjd8vkSKlrv4aceoVe2j5kAFeHT17T01nBb5XxWV-Kcck-ATx_yZb1ofLWyecuuJ2dX46nojmEQWRSrldCJtVGe4VQq0E5FhQ4sCd5pKIgKJ7eyyGniA0VgXajQIiQ4CQEbWjvKshDUO7Zb1RV8YBySPFEKnJNxFmUutDJQ-OlWJgWGdQEMmOjlbhaebcP0MLRb4_VkSE_G62nAkl45ZmvUGHQI_2h53OvS4A9FuyQozHrdGJlQCKtCnQ7Ye6_bTV8U0bOpOMb3bml9U4HIurfvVOWvlrQbJZamKv343z0-ZC_pyudBfmK7q-UaPmNAtHJHOODHP77Pj7qB_wQSqA3l |
link.rule.ids | 230,314,780,784,885,24116,27924,27925,45679 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBWlhW0vY9_LPjXYq4gtWbbzWLIGZ21CoSn0TUj29eZC7RAnsP2G_enda9lh2RiDvVqWLd8rXx1J5x4x9tEBwngJ-COp2IrIpSBsYEGkcWz1BAGHm1Du8GIZZ9fR5xt9c8SmQy4M0Sr72O9jehet-yvj3prjdVWNr6TGuYJS2CO7fGCMwyeIBhLs2ien8_NsuV9qIVUw3R28RlUE1RmS6Dqml71tvtyRnKeUHWlARn8bpP4Eob9zKX8ZnGaP2MMeVfJT3_DH7AjqJ-zeot83f8p-TJt2K7xScR_eeFPys2_NHfArz6bGMYwTR2PX8lVHD4eCkyg1v7Q1to0juuWXG6hpvYd_8gy9qnvMDOgSPn1HS28tt3XBl00t5pR7Ajz7Xmyadetvq9pn7Hp2tppmoj-GQeRRrLZCJ9ZGRY5TqUA7FZU6sGR4p6EkKZzCyrKgiQ-UgXWhwoiQ4CQEbGjtJM9DUM_Zcd3U8JJxSIpEKXBOxnmUu9DKQOGnW5mUCOsCGDEx2N2svdqGGWhot8b7yZCfjPfTiCWDc8xBrzE4IPyj5ofBlwZ_KNolQWM2u9bIhCCsCnU6Yi-8b_dtUSTPpuIY33vg9f0NJNZ9WFJXXzvRbrRYmqr01X-3-D27n60WF-Zivjx_zR5Qic-JfMOOt5sdvEVwtHXv-s7_E5IiD0s |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-Effectiveness+of+Exome+Sequencing+versus+Targeted+Gene+Panels+for+Prenatal+Diagnosis+of+Fetal+Effusions+and+Non-Immune+Hydrops+Fetalis&rft.jtitle=American+journal+of+obstetrics+%26+gynecology+MFM&rft.au=Avram%2C+Carmen+M&rft.au=Caughey%2C+Aaron+B&rft.au=Norton%2C+Mary+E&rft.au=Sparks%2C+Teresa+N&rft.date=2022-11-01&rft.eissn=2589-9333&rft.volume=4&rft.issue=6&rft.spage=100724&rft_id=info:doi/10.1016%2Fj.ajogmf.2022.100724&rft_id=info%3Apmid%2F35995366&rft.externalDocID=35995366 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2589-9333&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2589-9333&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2589-9333&client=summon |